/wp-content/uploads/logo-300x63.png
0
0
Emily Hennes
/wp-content/uploads/logo-300x63.png
Emily Hennes2021-11-16 18:15:432021-12-10 13:03:55Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities
/wp-content/uploads/logo-300x63.png
0
0
Emily Hennes
/wp-content/uploads/logo-300x63.png
Emily Hennes2021-11-16 18:13:522021-12-10 13:04:16Synthekine Strengthens Leadership with Board of Directors Expansion and Scientific Advisory Board Formation
/wp-content/uploads/logo-300x63.png
0
0
Emily Hennes
/wp-content/uploads/logo-300x63.png
Emily Hennes2021-11-16 18:11:242021-12-10 13:04:37Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T
/wp-content/uploads/logo-300x63.png
0
0
Emily Hennes
/wp-content/uploads/logo-300x63.png
Emily Hennes2021-11-16 18:07:262021-12-10 13:04:57Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases
Scroll to top
